/**

Valiant Organics FY26: A Margin-Led Turnaround After Two Weak Years

Valiant Organics Limited ended FY26 with a clear improvement in profitability, even as revenue stayed broadly flat. Consolidated revenue from operations for FY26 stood at INR 7,388 million, up 2.8% year-on-year from INR 7,188 million in FY25. The bigger story was margins. EBITDA rose to INR 882 million from INR 537 million, and the EBITDA margin expanded to 11.94% from 7.47%. Profit after tax swung to INR 332 million, compared with a loss of INR 34 million in FY25.

Q4 FY26 underscored this recovery. The company reported operational revenue of INR 2,178 million, EBITDA of INR 265 million, and PAT of INR 157 million. EBITDA margin for the quarter was 12.17% and PAT margin was 7.21%. Management described FY26 as a turnaround year, driven by focused operational execution and structural cost optimisation.

What drove the FY26 recovery

Management attributed the margin expansion to changes across major cost lines rather than only top-line growth. The company highlighted raw material optimisation, tighter overhead control, and improved operating leverage. FY26 total expenses declined to INR 6,506 million from INR 6,651 million in FY25, even as revenue increased. That combination supported a sharp rise in EBITDA.

Finance costs also moved in the right direction. Consolidated finance cost reduced to INR 182 million in FY26 from INR 236 million in FY25. Depreciation rose to INR 396 million from INR 358 million, indicating a higher fixed cost base, but the margin recovery was sufficient to absorb it.

A key disclosure in the presentation is that consolidated numbers across periods are not strictly comparable due to changes in the relationship with Valiant Laboratories Limited. Following dilution after an IPO by its material step-down subsidiary, Valiant Laboratories became an associate with effect from October 4, 2023, and the company states that consolidated financials of previous periods and YTD results are not comparable.

Business mix: chemistries and end-user exposure

Valiant Organics operates as a specialty chemical manufacturer with capabilities across chlorination, hydrogenation, ammonolysis, acetylation, sulphonation, and methoxylation. The company positions itself as one of the largest chlorophenol derivatives manufacturers globally, a leading manufacturer of benzene derivatives products, and one of the largest domestic PNA manufacturers.

For FY26, the company disclosed a revenue break-up by chemistry. Hydrogenation contributed 48% of revenue, ammonolysis 26%, chlorination 20%, and other chemistries 6%. The concentration in hydrogenation makes it the single most important driver of performance.

The FY26 revenue split by end-user industry shows meaningful diversification, though dyes and pigments remain the largest exposure. Dyes and pigments accounted for 45% of revenue, agro chemicals 24%, pharmaceuticals 21%, and specialty chemicals 10%.

Financial summary (Consolidated)

Q4 FY26 performance: strong exit quarter

Quarterly performance improved sharply in Q4 FY26 compared to Q3 FY26. Revenue from operations increased to INR 2,178 million from INR 1,593 million, and EBITDA rose to INR 265 million from INR 156 million. PAT increased to INR 157 million from INR 36 million.

The company also disclosed Q4 FY26 revenue and volume by chemistry. Hydrogenation revenue was INR 1,050 million with sales volumes of 5,491 MT. Ammonolysis revenue was INR 533 million with volumes of 5,405 MT. Chlorination revenue was INR 431 million with volumes of 3,487 MT. The “others” category, while smaller, rose to INR 163 million with volumes of 391 MT.

This exit-quarter strength supported the full-year margin improvement and indicates a better operational rhythm toward the end of FY26.

Manufacturing footprint and operating scale

Valiant Organics operates six manufacturing units across five locations and highlights five zero liquid discharge plants. The company states total production capacity of 70,000 TPA and a workforce of 900+ employees.

Capacity disclosures by unit include chlorination at Sarigam (18,000 MTPA), ammonolysis at Vapi (10,000 MTPA) and Tarapur (6,600 MTPA), hydrogenation and methoxylation at Jhagadia Unit 1 (28,800 MTPA), hydrogenation at Jhagadia Unit 2 (12,000 MTPA), and acetylation and sulphonation at Ahmedabad (1,800 MTPA).

Balance sheet signals to track

The consolidated balance sheet shows equity of INR 7,594 million and total assets of INR 12,308 million as of FY26. Current borrowings were INR 2,001 million and non-current borrowings were INR 526 million.

Two line items stand out for monitoring. Consolidated trade receivables increased to INR 2,433 million in FY26 from INR 1,769 million in FY25, and cash and cash equivalents were INR 18 million in FY26. While the company cites working capital efficiencies, receivables expansion suggests collections and credit terms will be important to track alongside EBITDA improvements.

Market data and ownership snapshot

As of March 31, 2026, the share price was INR 202.50, with a 52-week high of INR 508.30 and low of INR 195.20. Market capitalisation was INR 5,673.97 million, with 28.02 million equity shares outstanding. Promoters held 37.89%, public shareholders 61.83%, and FII ownership was 0.28%.

Key takeaways

FY26 marks a clear profitability-led turnaround for Valiant Organics. Revenue growth was modest, but structural cost actions and improved execution helped lift EBITDA margin to 11.94% and return the company to profitability. Q4 FY26 performance provides a stronger base entering the next year.

The company’s revenue mix highlights a heavy dependence on hydrogenation chemistry and significant exposure to dyes and pigments. Alongside the improved margin profile, investors will likely focus on whether the recovery is sustainable, how working capital behaves given the rise in receivables, and how the company navigates comparability issues in consolidated reporting following the change in status of Valiant Laboratories. */